Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10337423 | 1.00 | ATM (0.59) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL10337379 | 1.00 | ATM (0.59) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL10337249 | 1.00 | ATM (0.59) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL10337270 | 1.00 | ATM (0.59) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL10337408 | 1.00 | ATM (0.59) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL10337181 | 1.00 | ATM (0.59) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL9614401 | 1.00 | ATM (0.59) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL10337404 | 1.00 | ATM (0.59) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL10337223 | 1.00 | ATM (0.59) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL11547083 | 1.00 | ATM (0.59) | ATML3MBTL1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-4920101-A | FOR ENHANCING PENETRATION OF PHYSIOLOGICALLY ACTIVE AGENTS THROUGH SKIN OR OTHER MEMBRANES | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4879275-A | Penetration enhancers for transdermal delivery of systemic agent | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1989-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | ATM 4785/4885L3MBTL1 4862/4885MEN1 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.